Stenocare ASFRA:S7C 34 Pretax Margin % is -15.17% as of Mar. 2026. GuruFocus rates FRA:S7C with a GF Score™ of 34/100 and a GF Value™ of €0.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Stenocare AS ranks worse than 76.05% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Stenocare AS's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-0.06 Mil. Stenocare AS's Revenue for the
three
months ended in Mar. 2026 was €0.40 Mil. Therefore, Stenocare AS's pretax margin for the quarter that ended in Mar. 2026 was -15.17%.
The historical rank and industry rank for Stenocare AS's Pretax Margin % or its related term are showing as below:
FRA:S7C'
s Pretax Margin % Range Over the Past 10 Years
Min: -1550.04 Med: -398.4 Max: 45.45
Current: -9.25
FRA:S7C's Pretax Margin % is ranked worse than 76.05% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs FRA:S7C: -9.25
Stenocare AS (FRA:S7C) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Stenocare AS Pretax Margin % Related Terms
Stenocare AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Stenocare AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S7C vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Stenocare AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (FRA:S7C) has a Pretax Margin % of -15.17% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #727 out of 956 companies in the Drug Manufacturers industry, placing it in the top 76%.
Is Stenocare AS's Pretax Margin % too high?
Stenocare AS's current Pretax Margin % is -15.17%. Based on the distribution chart, Stenocare AS ranks #727 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #727 out of 956 companies for Pretax Margin %. This places Stenocare AS in the lower half of its industry. The industry median Pretax Margin % is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current Pretax Margin % is -15.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (FRA:S7C) is currently considered Possible Value Trap. The stock's GF Value™ is €0.29, compared to a current price of €0.13 — trading 56.9% below its estimated fair value. The current Pretax Margin % is -15.17%. Stenocare AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Pretax Margin % is -15.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.13 is trading 56.9% below its estimated GF Value™ of €0.29.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for FRA:S7C:
Pretax Margin %: -15.17%
GF Value™: €0.29 vs. price of €0.13 (56.9% below fair value)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
34GF Score
Get the complete analysis for FRA:S7C
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
